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Abstract 
Sofosbuvir is a potent HCV NS5B nucleotide polymerase inhibitor with broad genotypic coverage 
and low risk of developing drug resistance. While clinical studies have provided the effectiveness 
of sofosbuvir for treatment of patients with hepatitis C virus genotype 4 (HCV-4), however, many 
side-effects were reported. To reduce those side effects and improve the antiviral activity of the 
drug, sofosbuvir was encapsulated into chitosan nanoparticles (CNPs) to produce sofosbuvir 
encapsulated chitosan nanoparticles (SCNPs). 3D Molecular simulation and dynamics were made 
for sofosbuvir and SCNPs to evaluate the active sites of HCV-4 NS3 protease, NS5B polymerase 
and HCV helicase relative to both their catalytic activities and drug susceptibilities. The produced 
SCNPs were finally evaluated on hepatoblastoma cells (Huh7) for their antiviral efficiency. 
 
Methods: SCNPs were prepared by ionic gelation method and characterized by FTIR, TEM, Zeta 
sizer and U-Vis Spectrophotometry. The cytotoxicity of SCNPs were then performed on Huh7 
cells using flow cytometry and colorimetric MTT techniques. The anti HCV-4 activity of SCNPs 
was determined by quantitative real time PCR. Finally, the 3 D structure molecular modeling and 
simulation were made by Molegro Virtual Docker software and Swiss model server respectively. 
 
Results: The suggested chemical structure for SCNPs was confirmed by FTIR. The average 
particle size and surface charge of SCNPs were 137 ± 34 nm and 29 ± 9.6 mV respectively. The 
Encapsulation efficiency was 80% and the loading efficiency was 6%. The binding affinity of 
SCNPs with HCV-4 NS3, NS5B and NS5A were -156.512, -154.603 and -131 respectively. But 
for sofosbuvir were -127.581, -131.535 and -167 respectively based on the MolDock score. The 
treatment of HCV- 4 infected Huh7 cells with up to 100 μM of SCNPs neither showed significant 
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cytotoxic nor genotoxic effects after 48 hours of cell exposure. Finally, a complete disappearance 
of HCV RNA was seen after 24 hours of exposure to 100 μM of SCNPs when compared with the 
untreated cells.  
 
Conclusion: The SCNPs displayed potent anti HCV-4 activity in Huh7 cells with no apparent 
cellular toxicity. Molecular docking could be a promising tool for predicting novel antiviral agents 
in saving time, effort and cost before applying in vitro assays. We believe that this study provides 
promising application of CNPs as a safe nanocarrier for antiviral agents. 
 
Keywords: Sofosbuvir, Chitosan nanoparticles, Direct acting antiviral agents, cytotoxicity 
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1 Introduction 
Viral infections represent a major public health issue, with negative impacts not only on healthcare 
but also have numerous socioeconomic costs. Although, there are many antiviral agents available 
in the market with different antiviral mechanisms, viruses developed resistant to most of them. 
This is mainly due to their selective action against one virus or viruses belong to the same family 
as well as the absence of broad-spectrum antiviral agents. Therefore, there is a high demand for 
discovery of novel strategies to improve the antiviral therapies to control or limit the spread of 
infections.  
 
Hepatitis C is considered as a major problem worldwide with more than 200 million people 
infected globally. Egypt has the highest prevalence of hepatitis C (1). Hepatitis C infection is called 
the silent killer as it could infect the patients for long time without appearance of any symptoms 
until late stages of disease. Patient with chronic hepatitis suffer from weakness and jaundice with 
a possibility to extend to liver cirrhosis and hepatocellular carcinoma leading to death  (1). Efficient 
treatment of hepatitis C infections with conventional antiviral agents is hindered by the 
development of resistance to antiviral agents due to virus mutation  (2), and adverse side effects 
due to drug accumulation at off-target organs (3).  
 
Most recently, direct acting antiviral agents (DAA) such as protease, polymerase, NS5B or NS5A 
inhibitors were co-administered with ribavirin (double therapy) or with ribavirin and interferon 
(triple therapy) for treatment of hepatitis C virus (HCV) (4,5). Sofosbuvir (Sovaldi) is one of the 
most recent DAA that inhibits the replication of HCV through the inhibition of NS5B. However, 
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some major side effects, especially in kidney and liver, were reported when sofosbuvir were used 
clinically in Egyptian patients.  
This creates a huge pressure to develop novel antiviral agents to overcome these drawbacks. 
Nanoparticles (NPs) are considered as one of the most effective and novel therapeutic agents due 
to their potential ability to be tolerated and to target the therapeutic agent to the diseased organ 
with a concomitant decrease of off-target side effects (6).  
 
Chitosan is a naturally occurring cationic polysaccharide possesses mucoadhesive properties that 
enable its transport across the mucosal membrane and known to be biodegradable and compatible 
with biological system due to its biodegradation into nontoxic amino sugars that can be completely 
absorbed by the body (7). Chitosan nanoparticles has been reported to encapsulate several drug 
efficiently and target their delivery into the affected organ (7,8).  
 
In this work, we hypoethsis that sofosbuvir  as a model of DAA when encapsulated into chitosan 
nanoparticles, might be associated with an increase of its safety profile and improve its antiviral 
activity in vitro in Huh7 cells infected with HCV – 4 due to the potential delivery of the drug into 
the affected organ (passive targting) e.g. liver. Consequently, there is a high possibility of reducing 
dose and the frequency of administration required for a proper therapeutic management of infected 
patients. 
 
2. Materials and Methods 
2.1. Materials: Chitosan (low molecular weight), tripolyphosphate (TPP), ethanol, methanol, 
ethyl acetate, glutaraldehyde, and isopropanol were purchased from Sigma-Aldrich (St Louis, MO, 
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USA). MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reagent was 
purchased from Serva (Heidelberg, Germany). Dulbecco’s modified Eagle’s medium (DMEM), 
penicillin, streptomycin, and fetal bovine serum (FBS) were purchased from Gibco (Merelbeke, 
Belgium). Chitosan (low molecular weight), tripolyphosphate (TPP), ethanol, methanol, ethyl 
acetate, glutaraldehyde, and isopropanol were purchased from Sigma-Aldrich (St Louis, MO, 
USA). MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reagent was 
purchased from Serva (Heidelberg, Germany). Dulbecco’s modified Eagle’s medium (DMEM), 
penicillin, streptomycin, and fetal bovine serum (FBS) were purchased from Gibco (Merelbeke, 
Belgium). The Huh7 cells were supplied by Rockefeller University (New York, NY, USA). 
Sofosbuvir was a kind gift from Gilead company. 
 
2.2. Methodology   
2.2.1. Preparation of Sovaldi -chitosan nanoparticles (SCNPs) 
SCNPs was prepared by following the previously reported protocol (9). Briefly, sofosbuvir powder 
was dissolved in 3.8 ml of dimethyl sulfoxide to form 5 mM solution. Sofosbuvir solution was 
then added to the chitosan solution (1% acetic anhydride solution, 5 mg/ml, 100 ml) and mixed by 
continuous stirring for 1 h. The mixture was then neutralized by the addition of the negatively 
charged tripolyphosphate (TPP) solution (distilled water, 2.5 mg/ml, 67 ml), under magnetic 
stirring (500 rpm, 1 h) and at room temperature (11). The obtained NPs were then washed with 
distilled water (50 ml X 5) followed by centrifugation at 15,000 rpm to remove the residual acetic 
acid and other impurities. The produced pellets were re-suspended in distilled water by the help of 
vortex.   
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2.2.2. Characterization of SCNPs 
2.2.2.1. Transmission electron microscopy (TEM) 
SCNPs were imaged using TEM (H-700, Hitachi Ltd., Japan) at accelerated voltage of 80 KV. 
TEM was performed for identification of the sample uniformity, presence of aggregation (if any), 
shape, and size. After samples were applied on TEM grid, the grid was left to dry in air before 
imaging. 
 
2.2.2.2.Particle size and zeta potential: 
The particle size and their zeta potential were measured by zeta sizer (Malvern Instruments ZS 
NANO, UK).  Samples were diluted in distilled water to give count rates ranging from 50 to 300 
Kcps and the measurements were performed at 25 °C ± 0.1(7). 
2.2.2.3.Encapsulation efficiency and drug loading 
The encapsulation efficiency was determined by measuring the sample absorbance at ʎmax 260 nm 
using U-Vis Spectrophotometry (V-650 UV-VIS Spectrophotometer, Jasco, Japan). A calibration 
curve covering a concentration range of 0.5 to 5mM was constructed to calculate the encapsulation 
efficiency and the drug loading percentage using the following equations; 
Encapsulation Efficiency% = 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔 
 * 100 
                 Drug Loading % = 
𝑤𝑒𝑖𝑔ℎ𝑡  𝑜𝑓 𝐷𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑢𝑠𝑒𝑑 𝑡𝑜 𝑓𝑜𝑟𝑚 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
 * 100 
 
2.2.2.4.Fourier-transform infrared spectroscopy (FTIR) 
The FTIR was carried out for CNPs, Sovaldi, and SCNPs to show the interaction bonds between 
sovaldi and chitosan. FTIR was used with the following specifications: spectral range 400–4500 
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cm−1, number of scans 16, spectral resolution 4 cm−1. The software was Opus (Bruker 
(Germany), VERTEX 70, RAMII). 
2.2.3. Cytotoxicity study of SCNPs in vitro 
2.2.3.1.Cell Culture  
The human hepatoblastoma cell line, Huh 7 cells (ATCC, USA) was cultured by following the 
previous reported protcol (10) using Dulbecco’s Modified Eagle Medium (DMEM, Biowest, 
France) containing fetal bovine serum (10% Biowest, France) and antibiotics (100 IU/ml 
penicillin/streptomycin, Lonza, Belgium) as a growth medium. Cells were then maintained in a 
monolayer culture at 37oC under a humidified atmosphere and 5% CO2. Cells were routinely 
subcultured by trypsinization (Trypsin/versine, Lonza, Belgium). 
2.2.3.2.Microscopic study 
Huh7 Cells (3x106, 75cm2flask) (Corning, USA) were treated with SCNPs (100 µM) for 24 h. 
Cells were then washed with PBS buffer, fixed with 2% glutaraldehyde for 2 h, then washed twice 
with PBS and finally fixed in 1% OsO4 for 1 h. Following agarose (1.5%) enrobing, Spurr’s resin 
embedding, and ultrathin (50 nm) sectioning, the samples were stained with aqueous uranyl acetate 
(2% w/v) and lead citrate (25 mg/ml) and imaged with a JEOL 100S microscope (12). Another set 
of cells was prepared similary but with no treatment with SCNPs to act as Control. 
2.2.3.3.MTT assay to identify cell viability of cells treated with SCNPs 
We employed a modified method utilizing MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide dye (Serva Electrophoresis GmbH, Germany) that is based on the 
reduction of the dye by mitochondrial dehydrogenases of metabolically active cells into insoluble 
formazan crystals (10,13). Briefly, cell monolayers were treated in octuplet with control or test 
samples (sofosbuvir and SCNPs) for an exposure time of 48 h. At the end of exposure, MTT 
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solution in phosphate buffered saline (PBS) (5 mg/ml) was added to each well and incubated for 
90 min. The formation of formazan crystals was visually confirmed using phase contrast 
microscopy. DMSO (100 µl/well) was added to dissolve the formazan crystals with shaking for 10 
min. The absorbance was measured at 540 nm against Blank (media that doesn’t contain any cells) 
on a FLuo Star Optima microplate reader (BMG Technologies, Germany). Cell viability was 
calculated by comparing the OD values of the DMSO control wells with those of the samples and 
expressed as % viability to the control. Dose-response experiment was performed on samples 
producing ≥ 50% loss of cell viability using five serial 2-fold dilutions (100, 50, 25, 12.5 and 6.25 
µM) of the sample. Where applicable, IC50 values (concentration of sample causing 50% loss of 
cell viability of the control i.e. untreated cells) were calculated using the dose response curve fit 
to non-linear regression correlation using GraphPad Prism® V6.0 software. 
  % Viability of Huh7 cells =      (mean OD540 of test sample)   x100 
 
 
2.2.3.4. TEM and cellular uptake 
A similar set for cell treated with SCNPs (100µM) in section 2.2.3.3 was prepared but with no 
treatment with MTT reagent and these cells were imaged by TEM to identify the interaction and 
cellular localization of SCNPs in Huh 7 cells. 
2.2.3.5.Flow cytometry study to measure the effect of SCNPs on cell cycle of Huh7 cells 
Huh7 cells (5x105cells/well) were plated in 6-well microplates. After treatment with SCNPs (100 
µM), cells were trypsinized, washed twice with PBS, suspended in PBS (300 μl) and finally fixed 
with ice-cold 70% ethanol (4 ml). To stain with propidium iodide (PI), cell sedimentation was 
performed by centrifugation; the ethanol was removed and washed with PBS. The cell pellets were 
 (mean OD540 of control)  
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then resuspended in 1ml of PI/Triton X-100 staining solution (0.1% Triton X-100 in PBS, 0.2 
mg/ml RNase A, and 10 mg/ml PI) and incubated for 30 min at room temperature. The stained 
cells were analyzed using a MoFlo flow cytometer (DakoCytomation, Glostrup, Denmark) to 
calculate the fractions of cells in each phase of the cell cycle (14) versus another set of cells that 
was prepared similary but were not treated with SCNPs to act as a control.   
2.2.3.6.Identify DNA fragmentation for cells treated with SCNPs 
Fragmentation of cellular DNA was investigated following the treatment of Huh7 cells with 
Sovaldi, SCNPs (100 µM) for 24 h. A fixed amount (100 ng) of cellular DNA (Genomic DNA 
Purification Kit, Amersham Biosciences) extracted from SCNPs treated and untreated cells, were 
resolved on 1.5% agarose gel electrophoresis in Tris-acetate buffer pH 8.2 and stained with 0.5 
μg/ml ethidium bromide (EB). The DNA bands were examined under UV transillumination and 
photographed. Smearing, or presence of many low molecular weight DNA fragments are 
characteristic features of apoptotic cells (15). 
 
2.2.4. Antiviral activity of SCNPs 
2.2.4.1. Viral inoculation in Huh7 
Huh 7 Cells (106) were grown in 25 cm2 flask for 48 hr to semi-confluence in DMEM containing 
10% FBS, then, medium was removed and cells were washed twice with FBS-free medium, then 
inoculated with a serum sample  (500 μL sense) obtained from HCV-4 infected patients (RT-PCR 
and antibody positives) followed by addition of 500 μL of FBS-free DMEM. The HCV genotype 
in the applied sera was previously characterized as HCV-4 based on the method described by Ohno 
and his colleagues (16). The viral load was quantitated by real-time PCR and the average copy 
number was found to be 106 IU/ml. After 90 min, DMEM containing FBS was added to make the 
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overall serum contents around 10% in a final volume of 8 ml including the volume of human serum 
used for infection as mentioned above. Cells were maintained overnight at 37oC and 5% CO2. 
Adherent cells were then washed, three times, with culture medium to get rid of the remaining 
infection serum followed by addition of DMEM containing 10% FBS and cells were incubated  
for 48 h. Cells were harvested and assessed for the presence of HCV core proteins (17). Finally, 
quantitative PCR was performed (18). 
 
2.2.4.2.Antiviral assay of SCNPs in Huh7 
This was performed according to the previously published protocol by Hu and teamwork (17) and 
El Awady and his colleagues (19). Six well plates were seeded with 5x 105 cells/well. After 24 h, 
A 500 µl of the positive serum was then inoculated and kept for 90 min for virus adsorption onto 
cells. DMEM containing 10% FBS (2.5 ml) was added followed by incubation at 37 ْC and 5% 
CO2 for 24 h. Infected cells were treated with either sovaldi or SCNPs. Untreated infected cells ( 
Control) represent cells that are cultured similarly but with no Sovaldi treatment. The plates were 
then subjected to RNA extraction and real-time PCR assay according to the previously published 
protocol (20).  
2.2.5. In silico docking study of HCV-4 NS3, NS5A and NS5B Polymerase with Sovaldi and 
SCNPs 
The docking study was carried out on an Intel Dual-Core (1.8 GHz) Windows PC with Molegro 
Virtual Docker (MVD) 2013.6.0.0 (15). The two-dimensional structure of Nano-chitosan was 
converted to three-dimensional format for docking purposes using Schrödinger’s Materials 
Science Suite V2.6. Sovaldi ligand was obtained from PubChem Bioassay. In the absence of a 
crystal structure, homology models of NS3 protease and NS5A polymerase were built based on 
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the published cocrystal structure of NS3 protease and NS5A polymerase using SWISS-MODEL 
protein structure homology-modelling server (16–19). The crystallographic structure of NS5B 
polymerase was obtained from the protein data bank (4wtg pdb). 
 
3. Results 
3.1. Preparation and characterization of SCNPs:    
SCNPs were prepared by ionic gelation method following a previous reported protocol as 
described in section 2.2.1. Figures 1 showed TEM images of SCNPs, nanoparticles are spherical 
in shape and they are stable as revealed by the absence of aggregation. The particle size was 
presented as diameter ± Standard deviation and it was 137 ± 34 nm while zeta potential of SCNPs 
was 29 ± 9.6 mV. The encapsulation and loading percentage of Sovaldi were found to be 80% and 
6% respectively.  
 
 
                          Figure 1: TEM images of sovaldi-chitosan nanoparticles 
FTIR analysis showed the FT-IR spectra of the prepared CNPs and SCNPs. FTIR analysis depicts 
important absorption bands to identify the prepared CNPs. The stretching vibration of –OH bond 
was seen at 3430 cm-1 while the absorption peak at 2929cm-1 was appointed to a C-H stretching. 
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Finally, the absorption peaks at 1633 cm-1, 1543 cm-1 and 1385 cm-1 were associated with the 
presence of C=O stretching of the amide band, bending vibration of N-H and bending vibration of 
O-H bond respectively.  FTIR analysis showed the disappearance of the N-H peak and this 
indicative of the interaction between chitosan and sofosbuvir through the positively charged 
ammonium group of chitosan and the lone pair of electrons of sofosbuvir.  
 
3.1. Cytotoxicity test  
3.1.1. Light microscopy 
Figure 2 (A, and B) depict light microscopy images of the control and SCNPs (100 μM, 53 mg/ml) 
treated Huh7 cells respectively. The treated cells were exposed to SCNPs for 24 hr. Interestingly, 
SCNPs showed no profound morphological changes or apparent cytotoxic effects.  
 
3.1.2. Dose-dependent cytotoxicity effect of SCNPs on HepG2 cells 
Figure 3 A and B depict the cytotoxic effect of various concentrations of Sovaldi and SCNPs 
(5µM, 12.5 µM, 25µM, 50 µM and 100 µM) on the viability of Huh7 cells as determined by MTT 
A B
Figure 2: microscopic examination of Huh7 cells (A) Untreated and (B) treated
with sovaldi-chitosan nanoparticles (100µM)
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colorimetric assay after 48 h of exposure.  Both Sovaldi and SCNPs, at concentrations up to 100 
µM (53 mg/ml), did not reveal any cytotoxic effect over 48h. However, as revealed from Figure 
3A and B, cells treated with SCNPs proliferate more than those treated with Sovaldi as indicated 
by the percentage of cell viability. 
 
3.1.3. Localization of SCNPs in Huh7 Cells by TEM  
 
Figure 4 shows the localization of SCNPs in Huh7 as seen by TEM. Binding and internalization 
of SCNPs in Huh7 cells was identifies where clusters of SCNPs were seen attached onto the cell 
membrane confirming cellular uptake of these NPs. Examination of images at higher magnification 
power showed intracellular NPs clusters, mainly associated with the internal membranes, with 
most of the dispersed NPs in the cytoplasm.   
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3.2. Effect of SCNPs on cell cycle analysis 
Cells treated with 100 μM (53 mg/ml) of SCNPs were evaluated for cell cycle and DNA contents 
using flow cytometric analysis. Data presented in Table 1 and Figure 5 revealed similar cell cycle 
patterns of cellular growth in both treated and untreated cells with no obvious harmful effect was 
seen on the cellular viability after treatment with SCNPs. 
 
 
 
  
 
 
 
Figure 4: TEM images showed the localization of sovaldi- Chitosan 
nanoparticles in Huh7 Cells
Table 1: Cell cycle analysis of Huh7 cells treated with SCNPs versus untreated 
cells (control) 
Cell Cycle  G0-G1 G2-M G2/G1       S Diploid 
Control 71.07 % 4.98 % 2 23.95 % 100% 
SCNPs (100 µM) 68.72% 5.5% 2 25.78% 100 % 
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3.3. Effect of SCNPs on the Integrity of genomic DNA  
DNA fragmentation analysis was carried out with gel electrophoresis to investigate the effect of 
sovaldi and SCNPs on the genomic integrity of DNA. Figure 6 shows that the cellular DNA 
contents of the treated cells was not different from the control after 24 hr exposure time.  
 
 
 
Figure 5: Flow cytometry study showed cell cycle analysis of Huh7 cells (A) treated 
with sovaldi-chitosan nanoparticles (100 µM) versus (B) untreated cells. There is no 
obvious harmful effect due to cells treatment with SCNPs
A B
Figure 6: EB-stained gel electrophoresis of DNA extraction from Huh7 cells, control 
(untreated cells), CNPs treated cells (chitosan), Sovaldi treated cells (Sofosbuvir), and 
SCNPs treated cells (Sofo @ chitosan). No differences of cell DNA content was identified 
among treated and untreated cells.
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3.4.   Viral replication in Huh7 cells and antiviral activity of SCNPs 
Huh7 cells were incubated with HCV-4 infected human serums for 24 h, 48 h, and 72 h. The total 
cellular RNA was then extracted from both treated and untreated cells and was subjected to 
quantitative real-time PCR assay. Our results showed that, the intracellular viral load peaked after 
24 h post infection as presented in Table 2. Therefore, we used this incubation time for our 
preliminary investigation for the antiviral activity of the SCNPs where Huh7 cells were incubated 
with SCNPs (100 μM, 53 mg/ml) for 24h. This resulted in a complete disappearance of HCV RNA 
compared to the untreated infected cells as presented in Table 3. 
 
 
  
Table 2: Viral inoculation and detection of HCV RNA at different time intervals by 
quantitative real time PCR assay 
Time interval (h) Viral Load (IU/mL) 
Uninfected Huh7 cells (24) Below detection limit 
Post infection (24) 2× 106 
post infection (48) 5x105 
post infection (72) 9.6 x103 
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3.2.2. In silico docking study of HCV-4 NS3, NS5A and NS5B Polymerase with Sovaldi and 
SCNPs  
The in-silico docking study was performed to identify the interactions of Sovaldi and SCNPs with 
HCV-4 NS3, NS5B and NS5A based on MolDock score followed by Hydrogen Bond Interaction 
(H-bond) score. The binding affinity of Sovaldi, at the active site, showed the best docking score 
for NS5A polymerase, MolDock score (-167) where Sovaldi formed 8 H-bonds, one H-bond with 
each of Glu 116 and Arg 157 and two H-bonds with each of Ala 162, Glu 116 and Lys 164. The 
interaction of NS5A polymerase and SCNPs involved formation of 5 H-Bonds (One H-Bond with 
each of Arg 160, Leu 149 and Gly96 and (two H-bonds with Trp111) and the MolDock score was 
-131. 
However, SCNPs displayed a higher binding affinity for the active site of NS3 protease than 
Sovaldi, based on the MolDock score where Sovaldi formed 3 H-Bonds with each of Thr 76, Asn 
77 and Ser 181 with -127.581 MolDock score. Contrary to SCNPs where the predicted mode of 
Table 3.   Antiviral monitoring of Huh 7 cells treated with Sovaldi - Chitosan nanoparticles for 
24 h using quantitative PCR assay 
Sample CT value Viral load (IU/ml) 
HCV serum 28.42 24x104 
Control  33.38 7x103 
Sovaldi below detection limit <50 
SCNPs  below detection limit <50 
CT value means cycle threshold values of RT-PCR. 
Control, cells infected with HCV-4 but were not treated with Sovaldi or SCNPs 
Antiviral Therapies II, American Society for Virology (ASV), July, 2018 
  
 
20 
 
interaction of SCNPs and NS3 protease involved formation of 11 H-bonds, one H-bond with each 
of Asn 187, His 203, Gln 73, Pro 332, Ser 334, Thr 185 and Val 183. In addition, it forms two H-
bonds with both Asn 72 and Thr 331 with MolDock score equivalent to -156.512.  
In case of NS5B polymerase, the MolDock score for SCNPs was -154.603 compared to -131.535 
for Sovaldi and this is indicative of a better interaction between NS5B and SCNPs than Sovaldi. 
SCNPs interaction with NS5B (Figure 7) involved formation of 8 H-Bond, One H-bond with each 
of Asn 291, Asp 319, Cys 316 and Cys 366 and two hydrogen bonds with Asp 318. While Sovaldi 
formed 3 H bonds, each with Asn 291, Asp 319, Cys 316.  
 
4. Discussion 
Chronic HCV-4 infection and its complications (cirrhosis, liver cell failure, hepatocellular 
carcinoma (HCC)) represents one of the major health problem among Egyptian population (21). 
Currently, Egyptian governmental efforts are focused on fighting such a debilitating infection 
through research funding, awareness campaigns and scientific meetings. Fortunately, the NS5B 
Figure 7: NS5B polymerase structure and domains (A); Palm, thumb and
fingers are colored in blue, green and red respectively. SCNPs interaction with
the active site of NS5B polymerase (B).
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polymerase inhibitor (GS-7977; Sovaldi) was approved in Europe (22) and united states (23) for 
the treatment of chronic hepatitis C. These approvales have enabled the application of Sovaldi in 
Egypt. Sovaldi may be used in combination with ribavirin either in an interferon-free regimen or 
in combination with peginterferon-α. The application of Sovaldi depends on the genotype of the 
HCV and the patient compliance for interferon and/or ribavirin treatments. In contrast, some 
scientists reported that the viral mutations, therapeutic index, associated side effects, the need for 
antiviral targeting might be the major obstacles for application of Sovaldi in treatment of HCV 
(24).  
Nanoparticles (NPs) are considered as one of the most effective and novel therapeutic agents due 
to their potential ability to be tolerated and to target the therapeutic agent to the diseased organ 
with a concomitant decrease of off-target side effects as described earlier. Therefore, we 
encapsulated sofosbuvir into chitosan nanoparticles with a future aim of using a lower drug dose 
for treatment of HCV-4 infected patients due to the ability to target of sofosbuvir into liver.  
 
SCNPs prepared by ionic gelation method for the preparation of SCNPs of a size and zeta potential 
137 ± 34 nm and 29 ± 9.6 mV respectively. The loading percentage of sovaldi into chitosan NPs 
was calculated as previously described (25) and was 6% with an entrapment efficiency of 80%. 
The encapsulation of Sovaldi into Chitosan nanoparticles was further confirmed by FTIR analysis 
where we identified the disappearance of the N-H peak that is indicative of the interaction between 
chitosan and sofosbuvir through the positively charged ammonium group of chitosan and the lone 
pair of electrons of sofosbuvir.  Further studies are in progress to explore the binding reaction and 
the kinetic release profile of sovaldi from SCNPs.    
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We then performed several studies on cellular and molecular levels to prove the safety of the 
composite before exploring its antiviral activity. The treatment of Huh7 cells with sovaldi or 
SCNPs show neither toxic effects nor alterations in cellular morphology after incubation of cells 
with concentrations up to 100 μM (53 mg/ml) for 24 and 48 h. The cellular uptake of the produced 
SCNPs was similar to previous preparations from our laboratory regarding internalization and 
distribution in cytoplasm and nucleus (8). Flow cytometric analysis and cellular DNA 
fragmentation showed no cellular or molecular toxicity. These results are matched with other 
reported data (26) where human in vitro culture of fibroblasts treated with chitosan nanoparticles 
showed no cytotoxic effect as revealed by similar cell viability between cells treated with chitosan 
nanoparticles and control cells (cells cultured in the medium in the absence of chitosan 
nanoparticles)  
  
Huh7 cells were then infected with HCV-4 positive human sera, at viral loads > 2 x 106 IU/ml. 
Infected cells were subsequently exposed to either sovaldi or SCNPs. The viral replication (in the 
absence of sofosbuvir or SCNPs) reached a peak at 24 h. Treating these infected cells by sofosbuvir 
and SCNPs resulted in complete disappearance of HCV RNA.  
Molecular docking study showed that SCNPs form more stable complex with NS3 protease, and 
NS5B polymerase than Sovaldi as indicated by the docking score values recorded for NS3 and 
NS5B with SCNPs; -156.512 , -154.603 versus -127.581, -131.535 recorded with Sovaldi. 
Contrary to NS5A where a more stable complex formed with Sovaldi rather than SCNPs as 
revealed by their docking score value; -167 for Sovaldi versus -131 for SCNPs. These data 
reflected that SCNPs could potentiate the antiviral activity of Sovaldi when encapsulated into 
chitosan nanoparticles. 
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The obtained data suggested that the encapsulation of Sovaldi into chitosan nanoparticles would 
not negatively affect its antiviral activity, but it could be associated with a lower side effect. 
However, further in-vivo investigations are still under processing to assure the safety of sofosbuvir 
encapsulated chitosan nanoparticles. 
 
Conclusion  
Virus infections cause diseases of different severity ranged from mild infection e.g. common cold 
into life threatening diseases e.g. Human Immunodeficiency virus (HIV), Hepatitis B. Virus 
infections represent 44% of newly emerging infections. Although there are many efficient antiviral 
agents, they still have drawbacks due to accumulation at off target organs and developing of virus 
resistance due to virus mutation. Therefore, developing a delivery system that can selectively target 
drug into affected organs and avoid off target accumulation would be a highly advantageous 
strategy to improve antiviral therapy. In this work, we encapsulated Sovaldi, a direct acting 
antiviral agent into chitosan nanoparticles by ionic gelation method, the size of SCNPs was 137 ± 
34 nm and the nanoparticles were stable as indicated by zeta potential value, 29 ± 9.6 mV and 
TEM images. The percentage of drug encapsulation and loading was 80% and 6% respectively. 
These NPs displayed no cytotoxic or genotoxic effects on human liver cancer cells, Huh7 cells 
after exposure to a concentration up to 100 μM (53 mg/ml) for 24 h. Both Sovaldi and SCNPs 
showed potent anti HCV-4 activities at 100 μM (53 mg/ml). Molecular docking study showed that 
SCNPs  have a higher binding affinity to NS5B and NS3 and a lower binding affinity to NS5A 
than sovaldi. This is indicative of the better antiviral activity that might be offered by SCNPs 
compared to Sovaldi. Although our results are promising for the application of SCNPs as a novel 
delivery system for DAA, several studies are still required to explore the antiviral activity on the 
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replicating system, the minimum inhibitory concentrations and the optimum incubation time of 
the virus with human cells, in vitro, to fine-tune the produced SCNPs. 
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